# Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)

> **NCT02269059** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 13 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MK-7680

## Key facts

- **NCT ID:** NCT02269059
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-02
- **Final completion:** 2015-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269059, "Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02269059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*